Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis

Figures & data

Figure 1 Bone turnover marker (TRAP-5b, total-P1NP) levels. TRAP-5b and total-P1NP levels increased immediately following discontinuation of denosumab.

Abbreviations: Dmab, Denosumab; TRAP-5b, tartrate-resistant acid phosphatase type 5; total-P1NP, total N-terminal propeptide of type I procollagen.

Figure 2 2D-BMD levels measured by DXA. DXA revealed that there was a significant decrease in bone mineral density after discontinuation of denosumab treatment.

Abbreviations: 2D-BMD, two-dimensional bone mineral density; DXA, dual energy X-ray absorptiometry; Dmab, Denosumab; BMD, bone mineral density; LS, lumbar spine; FN, femoral neck.

Figure 3 3D-BMD levels measured by QCT. QCT revealed that there was a significant decrease in bone mineral density after discontinuation of denosumab treatment.

Abbreviations: 3D-BMD, three-dimensional bone mineral density; QCT, quantitative computed tomography; Dmab, denosumab; BMD, bone mineral density; LS, lumbar spine; TH, total hip.

Figure 4 Cortical parameters of the hip measured by QCT. QCT revealed that the cortical parameter (cortical thickness and cortical BMD) decreased after discontinuation of denosumab treatment.

Abbreviations: QCT, quantitative computed tomography; Dmab, Denosumab; C-thickness, cortical thickness; C-BMD, cortical bone mineral density.

Figure 5 Biomechanical parameters of the hip measured by QCT. QCT revealed that the BR (index of cortical instability) increased and CSMI (index of bending strength) decreased after discontinuation of denosumab treatment.

Abbreviations: QCT, quantitative computed tomography; Dmab, Denosumab; BR, buckling ratio; CSMI, cross-sectional moment of inertia.